Awakn Receives UK State Funding to Identify Optimal Pathway to Market In UK & US
Ketamine Wellness Centers (KWC) Launches Ketamine Wellness Integrative Therapist Directory Nation’s Largest Ketamine Therapy Provider
PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch Successfully delivered ketamine and KETABET™
Numinus Pilots Mental Health Program for Corporate Clients in Utah With companies investing more and
First Patient Dosed in Second Phase 2 Add-on Ketamine Trial in Treatment-resistant Depression (TRD) Dosing
PharmaTher Announces Positive Results from Study of KETABET™ for Depression KETABET™ (Ketamine and Betaine) shown
Ehave, Inc. Announces its KetaDASH Mobile Unit will be Delivered to Miami Beach on June
Awakn Life Sciences Initiates Follow-on Behavioral Study to Focus on Gambling Disorder Study Initiated Following
Ketamine Wellness Centers (KWC) Launches SPRAVATO® Nasal Spray Therapy in Minneapolis, Salt Lake City and
Why ketamine is a speedster antidepressant Several studies have found that ketamine produces a rapid
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application For The Treatment Of Behavioral Addictions
PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO Wearable
Novamind Launches Group Psychedelic Treatment for Frontline Workers After piloting the program for 9 months,
Awakn Life Sciences Completes World’s First Ketamine Study For A Range Of Behavioral Addictions Collectively,
Ketamine Wellness Centers (KWC) Announces Partnership With The Veterans Administration (VA) in Arizona Nation’s Largest
Field Trip and Nue Life Are Collaborating To Bring Psychedelic Therapy Into the Home Field
Cybin and Kernel Announce Results from Kernel Flow® Piloting of Feasibility Study Measuring Ketamine’s Effects
PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine
Ketamine Wellness Centers Introduces NAD+ Infusion Therapy KWC Becomes Largest Ketamine Provider in the U.S.
PharmaTher Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Recent Business
NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments
Wellbeing Digital Sciences Signs MOU with Pathway Health Regarding the Potential Sale of Certain Assets
Nue Life Health raises $23M Series A Led by Obvious Ventures for psychedelics platform Nue
NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation
